Search research articles
Contact Us
Filters
Showing results (1-10 of 20) with videos related to
Page
of 2
Sort By:
International Journal of Laboratory Hematology
|
September 12, 2022
Comparison of platelet count results on the Sysmex XN between citrate or MgSO<sub>4</sub> and K2 EDTA anticoagulants
Michel Soulard, Pascale Croix, Patrick Cohen
Journal of Clinical Medicine
|
September 28, 2024
Impact of Shaking EDTA, Citrate, or MgSO<sub>4</sub> Tubes on Platelet Count Results
Michel Soulard, Hela Ketatni, Claire Visseaux, et al.
International Journal of Laboratory Hematology
|
November 15, 2025
Comparison of Blood Cell Count Results Between MgSO<sub>4</sub> and K2EDTA. Stability and Accuracy of Platelet Counting With MgSO<sub>4</sub>
Michel Soulard, Hela Ketatni, Pascale Croix, et al.
The American Journal of Gastroenterology
|
September 1, 2005
Effect on intragastric pH of a PPI with a prolonged plasma half-life: comparison between tenatoprazole and esomeprazole on the duration of acid suppression in healthy male volunteers
Richard H Hunt, David Armstrong, Cindy James, et al.
CPT: Pharmacometrics & Systems Pharmacology
|
April 1, 2024
Joint modeling of tumor dynamics and progression-free survival in advanced breast cancer: Leveraging data from amcenestrant early phase I-II trials
Marc Cerou, Hoai-Thu Thai, Laure Deyme, et al.
Plos One
|
September 9, 2020
Identification of immunodominant linear epitopes from SARS-CoV-2 patient plasma
Lluc Farrera-Soler, Jean-Pierre Daguer, Sofia Barluenga, et al.
Proceedings of the National Academy of Sciences of the United States of America
|
May 4, 2021
A high-throughput microfluidic nanoimmunoassay for detecting anti-SARS-CoV-2 antibodies in serum or ultralow-volume blood samples
Zoe Swank, Grégoire Michielin, Hon Ming Yip, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
July 9, 2013
Phase I safety, pharmacokinetic and pharmacodynamic evaluation of the vascular disrupting agent ombrabulin (AVE8062) in patients with advanced solid tumors
Cristiana Sessa, Patricia Lorusso, Anthony Tolcher, et al.
Therapeutic Advances in Medical Oncology
|
March 21, 2022
AMEERA-5: a randomized, double-blind phase 3 study of amcenestrant plus palbociclib <i>versus</i> letrozole plus palbociclib for previously untreated ER+/HER2- advanced breast cancer
Aditya Bardia, Javier Cortes, Sara A Hurvitz, et al.
Cancer Discovery
|
May 17, 2012
Reversing resistance to vascular-disrupting agents by blocking late mobilization of circulating endothelial progenitor cells
Melissa Taylor, Fanny Billiot, Virginie Marty, et al.
Page
of 2
Search research articles
Search
Showing results (1-10 of 20) with videos related to
Sort By:
Page
of 2
International Journal of Laboratory Hematology
|
September 12, 2022
Comparison of platelet count results on the Sysmex XN between citrate or MgSO<sub>4</sub> and K2 EDTA anticoagulants
Michel Soulard, Pascale Croix, Patrick Cohen
Journal of Clinical Medicine
|
September 28, 2024
Impact of Shaking EDTA, Citrate, or MgSO<sub>4</sub> Tubes on Platelet Count Results
Michel Soulard, Hela Ketatni, Claire Visseaux, et al.
International Journal of Laboratory Hematology
|
November 15, 2025
Comparison of Blood Cell Count Results Between MgSO<sub>4</sub> and K2EDTA. Stability and Accuracy of Platelet Counting With MgSO<sub>4</sub>
Michel Soulard, Hela Ketatni, Pascale Croix, et al.
The American Journal of Gastroenterology
|
September 1, 2005
Effect on intragastric pH of a PPI with a prolonged plasma half-life: comparison between tenatoprazole and esomeprazole on the duration of acid suppression in healthy male volunteers
Richard H Hunt, David Armstrong, Cindy James, et al.
CPT: Pharmacometrics & Systems Pharmacology
|
April 1, 2024
Joint modeling of tumor dynamics and progression-free survival in advanced breast cancer: Leveraging data from amcenestrant early phase I-II trials
Marc Cerou, Hoai-Thu Thai, Laure Deyme, et al.
Plos One
|
September 9, 2020
Identification of immunodominant linear epitopes from SARS-CoV-2 patient plasma
Lluc Farrera-Soler, Jean-Pierre Daguer, Sofia Barluenga, et al.
Proceedings of the National Academy of Sciences of the United States of America
|
May 4, 2021
A high-throughput microfluidic nanoimmunoassay for detecting anti-SARS-CoV-2 antibodies in serum or ultralow-volume blood samples
Zoe Swank, Grégoire Michielin, Hon Ming Yip, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
July 9, 2013
Phase I safety, pharmacokinetic and pharmacodynamic evaluation of the vascular disrupting agent ombrabulin (AVE8062) in patients with advanced solid tumors
Cristiana Sessa, Patricia Lorusso, Anthony Tolcher, et al.
Therapeutic Advances in Medical Oncology
|
March 21, 2022
AMEERA-5: a randomized, double-blind phase 3 study of amcenestrant plus palbociclib <i>versus</i> letrozole plus palbociclib for previously untreated ER+/HER2- advanced breast cancer
Aditya Bardia, Javier Cortes, Sara A Hurvitz, et al.
Cancer Discovery
|
May 17, 2012
Reversing resistance to vascular-disrupting agents by blocking late mobilization of circulating endothelial progenitor cells
Melissa Taylor, Fanny Billiot, Virginie Marty, et al.
Page
of 2